NVCR News and Press, NovoCure Limited From 01/16/20

Let’s Just Say That I’m Early Right now, there are just no negatives ahead of us. Earnings so far are surprising to the upside, starting with the big financial names. This opens a window into the health of the economy from a macro perspective. The big banks are doing really...

Shares of NovoCure (NASDAQ: NVCR) , a medical device company focused on treating tumors , were up about 10% as of 3:20 p.m. EST on Thursday. There doesn't appear to be any company-specific news that can justify the move today. But NovoCure shared some bullish news with investors earlier in t...

The following slide deck was published by NovoCure Limited in conjunction with this Read more ...

I t’s So Easy to Stay Long and Trade, Right? How Can you Lighten Your Risk? You Can and You Should In my Sunday note, I was very cautious on high beta names. Of course, Tesla ( TSLA ) was my example and it promptly ran up 50 points yesterday on no new news. Stocks always seem to ma...

January 13, 2020 Palm Beach, FL – January 13, 2020 – The global pain management devices market size is expected to reach USD 9.3 billion by 2026 registering a CAGR of 7.6%, according to a new study by Grand View Research, Inc. The global prevalence of diabetes i...

Novocure (NASDAQ: NVCR ) reports operating statistics and preliminary net revenues for Q4 and FY 2019. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38 th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on Monday, Jan. 13, 2020 Fourth quarter and full year 2019 financial re...

My Sense of Risk is Heightened, Yet, We Could Run Much Higher for Longer. What To Do? I was hoping that this geopolitical brouhaha would moderate the rally to extend its life. A little reminder that stocks can go down as well as up is a very healthy lesson to reinforce. We need some weak...

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor ...

Shares of NovoCure (NASDAQ: NVCR) , which makes devices for treating cancerous solid tumors with electric fields, rocketed 152% higher last year, according to data from S&P Global Market Intelligence . That sizzling performance makes it one of last year's hottest healthcare stocks . Fo...